Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer
Authors:
Open Access
- 1 July 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-29
Abstract
As the feasibility of risk-adaptive bladder-sparing treatment is increasingly validated, the prospects for neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) are rapidly evolving. For patients seeking effective and tolerable treatment options, platinum-based chemotherapy, particularly dose-dense MVAC (ddMVAC), remains the preferred standard. However, the emergence of novel interventions such as immune checkpoint inhibitors (ICIs), FGFR inhibitors, and antibody–drug conjugates (ADCs) offers promising alternatives, especially for those ineligible for cisplatin-based regimens. Ongoing clinical trials, including KEYNOTE-B15, RC48-C017, and NIAGARA, are actively investigating the efficacy of combining these agents with existing neoadjuvant therapies, aiming to establish new first-line treatment options. Although predictive models based on histological features, DNA damage repair (DDR) genes, molecular subtyping, liquid biopsies, and in vitro organoids have demonstrated potential in guiding treatment selection, the clinical translation process remains slow. There is a pressing need to accelerate the exploration of genetic heterogeneity in MIBC and to validate the clinical utility of emerging biomarkers to optimize patient selection for neoadjuvant therapy. This review will comprehensively examine the evolution of neoadjuvant treatment paradigms, focusing on high-quality evidence from evidence-based medicine and translational clinical research, with the aim of enhancing and updating readers' knowledge of neoadjuvant therapy for MIBC and providing insights for future practice and research directions.Keywords
This publication has 205 references indexed in Scilit:
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapyThe Lancet Oncology, 2011
- A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladderCancer, 2008
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer - Nordic Cystectomy Trial 2Scandinavian Journal of Urology and Nephrology, 2002
- Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924Journal of Clinical Oncology, 2001
- Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group.1996
- Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder LesionJournal of Urology, 1988